IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.
-
Oktay Y
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Ülgen E
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Can Ö
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Akyerli CB
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Yüksel Ş
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Erdemgil Y
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Durası IM
Department of Biological Sciences and Bioengineering, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
-
Henegariu OI
Department of Neurosurgery, School of Medicine Yale University, New Haven, CT 06520, USA.
-
Nanni EP
Functional Genomics Center Zurich, UZH/ETH, Zurich, Switzerland.
-
Selevsek N
Functional Genomics Center Zurich, UZH/ETH, Zurich, Switzerland.
-
Grossmann J
Functional Genomics Center Zurich, UZH/ETH, Zurich, Switzerland.
-
Erson-Omay EZ
Department of Neurosurgery, School of Medicine Yale University, New Haven, CT 06520, USA.
-
Bai H
Department of Neurosurgery, School of Medicine Yale University, New Haven, CT 06520, USA.
-
Gupta M
Cancer Institute, University College London, 72 Huntley Street, WC1E 6DD, London, UK.
-
Lee W
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
-
Turcan Ş
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
-
Özpınar A
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Huse JT
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
-
Sav MA
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Flanagan A
Cancer Institute, University College London, 72 Huntley Street, WC1E 6DD, London, UK.
-
Günel M
Department of Neurosurgery, School of Medicine Yale University, New Haven, CT 06520, USA.
-
Sezerman OU
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Yakıcıer MC
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Pamir MN
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
-
Özduman K
Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
Show more…
Published in:
- Scientific reports. - 2016
English
The single nucleotide polymorphism rs55705857, located in a non-coding but evolutionarily conserved region at 8q24.21, is strongly associated with IDH-mutant glioma development and was suggested to be a causal variant. However, the molecular mechanism underlying this association has remained unknown. With a case control study in 285 gliomas, 316 healthy controls, 380 systemic cancers, 31 other CNS-tumors, and 120 IDH-mutant cartilaginous tumors, we identified that the association was specific to IDH-mutant gliomas. Odds-ratios were 9.25 (5.17-16.52; 95% CI) for IDH-mutated gliomas and 12.85 (5.94-27.83; 95% CI) for IDH-mutated, 1p/19q co-deleted gliomas. Decreasing strength with increasing anaplasia implied a modulatory effect. No somatic mutations were noted at this locus in 114 blood-tumor pairs, nor was there a copy number difference between risk-allele and only-ancestral allele carriers. CCDC26 RNA-expression was rare and not different between the two groups. There were only minor subtype-specific differences in common glioma driver genes. RNA sequencing and LC-MS/MS comparisons pointed to significantly altered MYC-signaling. Baseline enhancer activity of the conserved region specifically on the MYC promoter and its further positive modulation by the SNP risk-allele was shown in vitro. Our findings implicate MYC deregulation as the underlying cause of the observed association.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/254002
Statistics
Document views: 61
File downloads: